Radiation Dosimetry and Biodistribution of the Hypoxia Tracer F-18-EF5 in Oncologic Patients - UTU Research Portal

A1 Refereed original research article in a scientific journal

Radiation Dosimetry and Biodistribution of the Hypoxia Tracer F-18-EF5 in Oncologic Patients

Authors: Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, Divgi C, Eskola O, Sorger JM, Stabin MG, Kachur A, Hahn SM, Gronroos TJ, Forsback S, Evans SM, Koch CJ, Minn H

Publisher: MARY ANN LIEBERT INC

Publication year: 2012

Journal: Cancer Biotherapy and Radiopharmaceuticals

Journal name in source: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Journal acronym: CANCER BIOTHER RADIO

Number in series: 7

Volume: 27

Issue: 7

First page : 412

Last page: 419

Number of pages: 8

ISSN: 1084-9785

DOI: https://doi.org/10.1089/cbr.2011.1130(external)

Abstract

Conclusions: F-18-EF5 was demonstrated to be safe for patients, and the radiation exposure is clinically acceptable. As with any radiotracer with primary excretion in the urine, the bladder-wall dose can be minimized by active hydration and frequent voiding.